ArticleBlood advances2026
Modulation of the bone marrow microenvironment by acute B-cell lymphoblastic leukemia-derived large oncosomes.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractWithin the bone marrow microenvironment, leukemia cells can hijack regulatory intercellular communication routes usually used by benign hematopoietic cells and establish a microenvironment permissive for chemotherapy/therapy-evasive growth. An important means of transmitting signals by leukemia cells is the release of extracellular vesicles (EVs). Large oncosomes (LO) are a distinct population of EVs known to contribute to aggressive growth in solid tumors. Here, we show that breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1)+ B-cell acute lymphoblastic leukemia (B-ALL) cells release LO capable of reprogramming primary mesenchymal stromal cells (MSC) toward a tumor growth-supportive phenotype. Transcriptome analysis combined with targeted secretome profiling of MSC revealed that BCR-ABL1+ B-ALL cells use LO to modulate pathways previously shown to regulate the availability of insulin-like growth factor 1 (IGF1) in the bone marrow microenvironment. Specifically, LO-conditioned MSC secrete less inhibitory IGF-binding proteins and show altered expression of extracellular matrix-degrading fibrinolytic proteins. Furthermore, LO metabolically reprogram MSC and prime MSC toward differentiation into adipocytes capable of sustaining B-ALL cell growth. Thus, LO-educated MSC, and the adipocytes derived from them, support B-ALL cells by distinct mechanisms, and targeting of LO-mediated communication pathways to prevent B-ALL progression has potential for the development of novel adjuvant treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.